MA41237B1 - Nouveaux peptides et combinaisons de peptides pour une utilisation en immunothérapie contre le carcinome hépatocellulaire (chc) et autres cancers - Google Patents
Nouveaux peptides et combinaisons de peptides pour une utilisation en immunothérapie contre le carcinome hépatocellulaire (chc) et autres cancersInfo
- Publication number
- MA41237B1 MA41237B1 MA41237A MA41237A MA41237B1 MA 41237 B1 MA41237 B1 MA 41237B1 MA 41237 A MA41237 A MA 41237A MA 41237 A MA41237 A MA 41237A MA 41237 B1 MA41237 B1 MA 41237B1
- Authority
- MA
- Morocco
- Prior art keywords
- cells
- peptides
- tumor
- present
- relates
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 8
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 title 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 230000005975 antitumor immune response Effects 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 1
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000011224 anti-cancer immunotherapy Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/00111—Hepatocyte growth factor receptor [HGFR or c-met]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
Abstract
La présente invention concerne des peptides, des protéines, des acides nucléiques et des cellules pour une utilisation dans des méthodes immunothérapeutiques. La présente invention concerne en particulier l'immunothérapie anticancéreuse. La présente invention concerne en outre des épitopes peptidiques tumoraux de cellules t, seuls ou combinés à d'autres peptides tumoraux, qui peuvent par exemple servir en tant que principes actifs pharmaceutiques au sein de compositions vaccinales destinées à stimuler une réponse immunitaire antitumorale ou destinées à stimuler ex vivo des cellules t ensuite transférées au patient. Des peptides liés aux molécules du complexe majeur d'histocompatibilité (cmh), ou les peptides en tant que tels, peuvent également être les cibles d'anticorps, de récepteurs solubles des cellules t, et d'autres molécules de liaison. La présente invention concerne en particulier plusieurs nouvelles séquences peptidiques et leurs variants dérivés de molécules du hla de classe i et de classe ii de cellules tumorales humaines, lesquels peuvent être utilisés dans des compositions vaccinales pour induire une réponse immunitaire antitumorale, ou comme cibles pour le développement de composés et de cellules pharmaceutiquement/immunologiquement actifs.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462096165P | 2014-12-23 | 2014-12-23 | |
GB201423016 | 2014-12-23 | ||
GBGB1501017.6A GB201501017D0 (en) | 2014-12-23 | 2015-01-21 | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
PCT/EP2015/080018 WO2016102272A1 (fr) | 2014-12-23 | 2015-12-16 | Nouveaux peptides et combinaisons de peptides pour une utilisation en immunothérapie contre le carcinome hépatocellulaire (chc) et autres cancers |
EP15813809.9A EP3236985B2 (fr) | 2014-12-23 | 2015-12-16 | Nouveaux peptides et combinaisons de peptides pour une utilisation en immunothérapie contre le carcinome hépatocellulaire (chc) et autres cancers |
Publications (2)
Publication Number | Publication Date |
---|---|
MA41237A MA41237A (fr) | 2017-11-01 |
MA41237B1 true MA41237B1 (fr) | 2019-12-31 |
Family
ID=52630910
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA40136A MA40136A1 (fr) | 2014-12-23 | 2015-12-16 | Nouveaux peptides et combinaisons de peptides pour une utilisation en immunothérapie contre le carcinome hépatocellulaire (chc) et autres cancers |
MA49158A MA49158B1 (fr) | 2014-12-23 | 2015-12-16 | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers |
MA41237A MA41237B1 (fr) | 2014-12-23 | 2015-12-16 | Nouveaux peptides et combinaisons de peptides pour une utilisation en immunothérapie contre le carcinome hépatocellulaire (chc) et autres cancers |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA40136A MA40136A1 (fr) | 2014-12-23 | 2015-12-16 | Nouveaux peptides et combinaisons de peptides pour une utilisation en immunothérapie contre le carcinome hépatocellulaire (chc) et autres cancers |
MA49158A MA49158B1 (fr) | 2014-12-23 | 2015-12-16 | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers |
Country Status (25)
Country | Link |
---|---|
US (8) | US10064926B2 (fr) |
EP (8) | EP3616706B1 (fr) |
JP (2) | JP6906156B2 (fr) |
KR (1) | KR102284493B1 (fr) |
CN (4) | CN112538109A (fr) |
AR (2) | AR103220A1 (fr) |
AU (3) | AU2015371490B2 (fr) |
BR (1) | BR112017008972A2 (fr) |
CA (1) | CA2972126A1 (fr) |
CL (1) | CL2017001391A1 (fr) |
CR (1) | CR20170282A (fr) |
DK (4) | DK3626731T3 (fr) |
EA (2) | EA202190587A3 (fr) |
GB (1) | GB201501017D0 (fr) |
IL (1) | IL250989B (fr) |
MA (3) | MA40136A1 (fr) |
MX (1) | MX2017008329A (fr) |
PE (1) | PE20170940A1 (fr) |
PH (1) | PH12017500484A1 (fr) |
PL (1) | PL3236985T5 (fr) |
RS (4) | RS62448B1 (fr) |
SG (1) | SG11201703322UA (fr) |
SI (3) | SI3545965T1 (fr) |
TW (1) | TWI687436B (fr) |
WO (1) | WO2016102272A1 (fr) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10322949B2 (en) | 2012-03-15 | 2019-06-18 | Flodesign Sonics, Inc. | Transducer and reflector configurations for an acoustophoretic device |
US10689609B2 (en) | 2012-03-15 | 2020-06-23 | Flodesign Sonics, Inc. | Acoustic bioreactor processes |
US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
US9752113B2 (en) | 2012-03-15 | 2017-09-05 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
US9745548B2 (en) | 2012-03-15 | 2017-08-29 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
US10737953B2 (en) | 2012-04-20 | 2020-08-11 | Flodesign Sonics, Inc. | Acoustophoretic method for use in bioreactors |
US9745569B2 (en) | 2013-09-13 | 2017-08-29 | Flodesign Sonics, Inc. | System for generating high concentration factors for low cell density suspensions |
WO2015105955A1 (fr) | 2014-01-08 | 2015-07-16 | Flodesign Sonics, Inc. | Dispositif d'acoustophorèse avec double chambre acoustophorétique |
US10813984B2 (en) * | 2014-04-24 | 2020-10-27 | Rhode Island Hospital | Aspartate-β-hydroxylase induces epitope-specific T cell responses in tumors |
US9744483B2 (en) | 2014-07-02 | 2017-08-29 | Flodesign Sonics, Inc. | Large scale acoustic separation device |
GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
TN2017000204A1 (en) | 2014-12-23 | 2018-10-19 | Novartis Ag | Triazolopyrimidine compounds and uses thereof |
PL3616706T3 (pl) | 2014-12-23 | 2022-02-07 | Immatics Biotechnologies Gmbh | Nowe peptydy i kombinacja peptydów do stosowania w immunoterapii względem raka komórek wątroby (HCC) i innych rodzajów raka |
US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
WO2017079703A1 (fr) | 2015-11-05 | 2017-05-11 | Juno Therapeutics, Inc. | Vecteurs et cellules immunitaires génétiquement modifiées exprimant des modulateurs de voie métabolique et utilisations en thérapie cellulaire adoptive |
AU2016369519B2 (en) | 2015-12-16 | 2023-04-20 | Gritstone Bio, Inc. | Neoantigen identification, manufacture, and use |
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
ES2798424T3 (es) | 2016-06-20 | 2020-12-11 | Novartis Ag | Compuestos de triazolopiridina y usos de estos |
WO2017221100A1 (fr) | 2016-06-20 | 2017-12-28 | Novartis Ag | Composés d'imidazopyrimidine utiles pour le traitement du cancer |
CN109563100B (zh) | 2016-06-20 | 2021-08-27 | 诺华股份有限公司 | 三唑并嘧啶化合物的晶体形式 |
US10858642B2 (en) * | 2016-10-07 | 2020-12-08 | Io Biotech Aps | Immunogenic arginase peptides |
JP2020513248A (ja) | 2016-10-19 | 2020-05-14 | フロデザイン ソニックス, インク.Flodesign Sonics, Inc. | 音響による親和性細胞抽出 |
DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
EP4317432A3 (fr) | 2016-12-08 | 2024-04-17 | Immatics Biotechnologies GmbH | Récepteurs de lymphocytes t à appariement amélioré |
CR20190388A (es) * | 2017-01-27 | 2019-10-16 | Immatics Biotechnologies Gmbh | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer |
EP3638695A4 (fr) * | 2017-06-14 | 2021-06-30 | Icahn School of Medicine at Mount Sinai | Procédés pour la détection et le traitement de classes de carcinome hépatocellulaire sensible à une immunothérapie |
DE102017115966A1 (de) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Polypeptidmolekül mit verbesserter zweifacher Spezifität |
PE20200614A1 (es) | 2017-07-14 | 2020-03-11 | Immatics Biotechnologies Gmbh | Molecula de polipeptido con especificidad dual mejorada |
CN111094582A (zh) * | 2017-08-09 | 2020-05-01 | 帕姆基因有限公司 | 预测非小细胞肺癌患者对药物的反应的方法 |
GB201713700D0 (en) * | 2017-08-25 | 2017-10-11 | Anastasis Biotec Ltd | Peptide conjugates |
AU2018348165A1 (en) | 2017-10-10 | 2020-05-21 | Gritstone Bio, Inc. | Neoantigen identification using hotspots |
JP2021503897A (ja) | 2017-11-22 | 2021-02-15 | グリットストーン オンコロジー インコーポレイテッド | 新生抗原のためのジャンクションエピトープ提示の低減 |
CA3085784A1 (fr) | 2017-12-14 | 2019-06-20 | Flodesign Sonics, Inc. | Circuit d'attaque et regulateur de transducteur acoustique |
CA3101310A1 (fr) * | 2018-03-12 | 2019-09-19 | The Children's Hospital Of Philadelphia | Procedes et compositions pour l'utilisation d'auto-antigenes tumoraux en immunotherapie adoptive |
DE102018122546B3 (de) * | 2018-09-14 | 2019-12-05 | Immatics Biotechnologies Gmbh | Verfahren zum Hochdurchsatz-Peptid-MHC-Affinitätsscreening für TCR-Liganden |
WO2020084621A1 (fr) * | 2018-10-26 | 2020-04-30 | Tami Bar | Compositions et procédés pour la biodégradation de l'alcool |
CN109663128A (zh) * | 2018-11-21 | 2019-04-23 | 中国农业大学 | 一种肺动脉高压标志物及其作为治疗靶点的应用 |
CN113747914A (zh) * | 2018-12-13 | 2021-12-03 | 罗得岛医院 | 抑制表达asph的肿瘤生长和进展 |
EP3721899A1 (fr) | 2019-04-08 | 2020-10-14 | China Medical University | Polythérapies comprenant un vaccin basé sur des cellules dendritiques et inhibiteur de point de contrôle immunitaire |
CN110850086B (zh) * | 2019-11-18 | 2023-05-02 | 西安交通大学 | 一种肝移植术后缺血性胆道病变血清诊断标志物acly的应用 |
CN113388024A (zh) * | 2020-03-18 | 2021-09-14 | 北京鼎成肽源生物技术有限公司 | 一种输卵管癌靶标抗原、输卵管癌靶标抗原刺激培养的ctl细胞及其应用 |
JP2023520475A (ja) * | 2020-03-30 | 2023-05-17 | ロペルバイオ カンパニー リミテッド | 免疫抗がん療法に対するバイオマーカーおよびその用途 |
US20220017636A1 (en) | 2020-05-19 | 2022-01-20 | Amgen Inc. | Mageb2 binding constructs |
CN112063718A (zh) * | 2020-09-18 | 2020-12-11 | 中国医科大学 | Usp14在肝细胞肝癌诊断、预后判断以及治疗中的应用 |
CN112043722B (zh) * | 2020-09-25 | 2022-02-15 | 中国医科大学 | Prpf6在前列腺癌及去势抵抗前列腺癌治疗中的应用 |
CN114574486B (zh) * | 2020-12-01 | 2024-04-16 | 中国科学院大连化学物理研究所 | 作用于OPLAH的siRNA、DNA及构建物和应用 |
AR125290A1 (es) | 2021-04-02 | 2023-07-05 | Amgen Inc | Construcciones de unión a mageb2 |
AU2022314744A1 (en) * | 2021-07-19 | 2024-02-08 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Mct11 antibodies to treat t cell functional exhaustion and enhance cancer immunotherapy |
CN113502300B (zh) * | 2021-07-21 | 2024-02-06 | 徐州医科大学 | 一种含有hdac10基因启动子序列和报告基因的重组质粒、制备方法及应用 |
CN115572764A (zh) * | 2022-03-30 | 2023-01-06 | 江苏鹍远生物技术有限公司 | 一组肿瘤检测标志物及其用途 |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
LU88257I2 (fr) | 1978-12-22 | 1994-02-03 | ||
US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
DK0701571T3 (da) | 1993-06-03 | 1997-09-15 | Therapeutic Antibodies Inc | Antistoffragmenter til terapi |
AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
DE69723230T2 (de) | 1996-01-17 | 2004-05-27 | Imperial College Innovations Ltd. | Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl) |
US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
AU2061201A (en) * | 1999-12-17 | 2001-06-25 | Chiron Corporation | Mammalian dishevelled-associated proteins |
AU2001232204A1 (en) | 2000-02-22 | 2001-09-03 | Ahuva Nissim | Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof |
JP2004503213A (ja) | 2000-03-27 | 2004-02-05 | テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド | 1本鎖クラスi主要組織適合性複合体、それをコードする構築物およびそれを生成する方法 |
US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
CN101712721A (zh) | 2000-06-05 | 2010-05-26 | 阿尔托生物科学有限公司 | T细胞受体融合物及共轭物以及其使用方法 |
US20020048550A1 (en) | 2000-07-20 | 2002-04-25 | Vallera Daniel A. | Radiolabeled immunotoxins |
US6867283B2 (en) | 2001-05-16 | 2005-03-15 | Technion Research & Development Foundation Ltd. | Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells |
US20050053918A1 (en) | 2001-05-16 | 2005-03-10 | Technion Research & Development Foundation Ltd. | Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses |
US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
AU2003216341A1 (en) | 2002-02-20 | 2003-09-09 | Dyax Corporation | Mhc-peptide complex binding ligands |
US7311914B2 (en) | 2002-08-13 | 2007-12-25 | Ludwig Institute For Cancer Research | MAGE-A4 antigenic peptides and uses thereof |
JP4406607B2 (ja) * | 2002-08-26 | 2010-02-03 | オンコセラピー・サイエンス株式会社 | ペプチド及びこれを含む医薬 |
CA2501870C (fr) | 2002-10-09 | 2013-07-02 | Avidex Limited | Recepteurs de lymphocytes t de recombinaison a chaine unique |
NZ570811A (en) | 2002-11-09 | 2009-11-27 | Immunocore Ltd | T cell receptor display |
US20040096982A1 (en) | 2002-11-19 | 2004-05-20 | International Business Machines Corporation | Methods and apparatus for analysis of mass spectra |
DE602004015064D1 (de) * | 2003-01-06 | 2008-08-28 | Wyeth Corp | Zusammensetzungen und verfahren zur diagnose und behandlung von kolonkrebs |
GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
US20090304679A1 (en) | 2004-05-27 | 2009-12-10 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
US20090233318A1 (en) | 2004-12-28 | 2009-09-17 | Weidanz Jon A | Methods of assaying vaccine potency |
US20090075304A1 (en) | 2004-05-27 | 2009-03-19 | Weidanz Jon A | Methods of assaying vaccine potency |
DK1806359T3 (da) | 2005-09-05 | 2010-06-14 | Immatics Biotechnologies Gmbh | Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler |
DE602005016112D1 (de) | 2005-09-05 | 2009-10-01 | Immatics Biotechnologies Gmbh | Tumorassoziierte Peptide, die HLA Klasse I oder II-Moleküle binden, und anti-Tumor Impfstoffe |
WO2008021290A2 (fr) | 2006-08-09 | 2008-02-21 | Homestead Clinical Corporation | Protéines spécifiques d'organes et procédés d'utilisation |
AU2008281015B2 (en) * | 2007-07-27 | 2012-07-26 | Immatics Biotechnologies Gmbh | Novel immunotherapy against neuronal and brain tumors |
DK2567707T3 (en) * | 2007-07-27 | 2017-07-31 | Immatics Biotechnologies Gmbh | Composition of tumour-associated peptides and related anti-cancer vaccine |
WO2009026547A1 (fr) | 2007-08-22 | 2009-02-26 | Receptor Logi, Ltd. | Procédés d'analyse de l'activité de vaccin |
ES2573458T3 (es) * | 2007-09-14 | 2016-06-08 | Vrije Universiteit Brussel | Mejoramiento de la capacidad estimulatoria de las células T de las células que presentan antígeno humano y su uso en vacunación |
EP2262834A4 (fr) * | 2008-02-27 | 2011-08-17 | Receptor Logic Inc | Anticorps imitant les récepteurs des lymphocytes t, leurs procédés de production et d utilisation |
PT2105501E (pt) * | 2008-03-27 | 2015-12-21 | Immatics Biotechnologies Gmbh | Nova imunoterapia para tumores neuronais e cerebrais |
US20090263574A1 (en) | 2008-04-21 | 2009-10-22 | Quinn Daniel E | Method of restoring an article |
WO2009151487A1 (fr) * | 2008-06-13 | 2009-12-17 | Receptor Logic, Inc. | Procédés de dosage de la puissance d’un vaccin |
DE102008049136B4 (de) | 2008-09-26 | 2012-10-25 | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. | Neue Regulatoren des angeborenen Immunsystems |
ES2536465T3 (es) | 2008-10-01 | 2015-05-25 | Immatics Biotechnologies Gmbh | Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres |
CA2780753A1 (fr) | 2009-11-14 | 2011-05-19 | Kuang-Yuh Chyu | Procedes et systemes d'immunomodulation pour le traitement et/ou la prevention de l'atherosclerose |
US8506964B2 (en) | 2010-02-05 | 2013-08-13 | Cardiovax, Llc | Fusion proteins and related compositions, methods and systems for treatment and/or prevention of atherosclerosis |
GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
US20140170168A1 (en) | 2010-10-26 | 2014-06-19 | Yoram Reiter | Antibodies which bind soluble t-cell receptor ligands |
US20130302362A1 (en) | 2010-11-12 | 2013-11-14 | Cedars-Sinai Medical Center | Immunomodulatory Compositions, Methods and Systems Comprising Immunogenic Fragments of ApoB-100 |
CN103501806A (zh) | 2010-11-12 | 2014-01-08 | 赛达斯西奈医疗中心 | 用于治疗和/或预防动脉瘤的免疫调节方法和系统 |
CA2817543A1 (fr) | 2010-11-12 | 2012-06-07 | Cedars-Sinai Medical Center | Procedes et systemes immunomodulateurs pour le traitement et/ou la prevention de l'hypertension |
WO2013057586A1 (fr) | 2011-10-19 | 2013-04-25 | Oslo Universitetssykehus Hf | Compositions et procédés de production de récepteurs solubles des lymphocytes t |
US9221876B2 (en) * | 2011-11-11 | 2015-12-29 | Cardiovax, Llc | Methods for treating kidney disease with fragments of ApoB-100 |
GB201208293D0 (en) * | 2012-05-11 | 2012-06-20 | Circassia Ltd | Hydrochlorice salt of peptide |
WO2014039675A2 (fr) * | 2012-09-05 | 2014-03-13 | University Of Virginia Patent Foundation | Peptides cibles pour la thérapie et les diagnostics du cancer colorectal |
ES2603589T3 (es) | 2012-11-08 | 2017-02-28 | F. Hoffmann-La Roche Ag | Ácidos nucleicos que codifican polipéptidos quiméricos para la identificación sistemática de bibliotecas |
GB201301632D0 (en) * | 2013-01-30 | 2013-03-13 | Imp Innovations | Complement System |
US9134326B2 (en) * | 2013-03-14 | 2015-09-15 | Battelle Memorial Institute | Biomarkers for liver fibrosis |
EP2808392A1 (fr) | 2013-05-28 | 2014-12-03 | Rheinische Friedrich-Wilhelms-Universität Bonn | Aptamères et utilisation de ces aptamères dans le diagnostic et le traitement du cancer |
CN103739667B (zh) * | 2013-09-24 | 2017-08-25 | 上海宇研生物技术有限公司 | 卵巢癌特异的肿瘤抗原肽及其制备方法 |
SG11201607181WA (en) | 2014-03-14 | 2016-09-29 | Immunocore Ltd | Tcr libraries |
GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
GB201507719D0 (en) * | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
US20180179283A1 (en) | 2015-06-08 | 2018-06-28 | Adicet Bio Inc. | T cell receptor like antibodies having fine specificity |
NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
CA3020555A1 (fr) | 2016-04-08 | 2017-10-12 | Adaptimmune Limited | Recepteurs des lymphocytes t |
RU2018138838A (ru) | 2016-04-08 | 2020-05-14 | Адаптимьюн Лимитед | Т-клеточные рецепторы |
CA3020530A1 (fr) | 2016-04-08 | 2017-10-12 | Adaptimmune Limited | Recepteurs de lymphocytes t |
WO2018022573A1 (fr) | 2016-07-27 | 2018-02-01 | Sharp Laboratories Of America, Inc. | Procédés et appareil de télécommunication sans fil utilisant une étiquette de valeur d'information système |
CN110809580A (zh) | 2017-01-24 | 2020-02-18 | 安贝科思生物制剂公司 | 用于靶向癌症中包含非典型hla-i和新抗原的复合体的方法和组合物 |
US20200325244A1 (en) | 2020-05-18 | 2020-10-15 | Abexxa Biologics, Inc. | Antibodies and methods of use thereof |
CN110709516B (zh) | 2017-06-05 | 2023-06-27 | 国立大学法人三重大学 | 识别来自mage-a4的肽的抗原结合性蛋白 |
BR112019028280A2 (pt) | 2017-07-04 | 2020-07-14 | Curevac Ag | moléculas de ácido nucleico |
JP2021500852A (ja) | 2017-08-18 | 2021-01-14 | グリットストーン オンコロジー インコーポレイテッド | 共有抗原を標的にする抗原結合タンパク質 |
US20190201443A1 (en) | 2017-09-06 | 2019-07-04 | California Institute Of Technology | Signaling and antigen-presenting bifunctional receptors (sabr) |
EP3731876A4 (fr) | 2017-12-28 | 2022-04-06 | Gritstone bio, Inc. | Protéines se liant à l'antigène ciblant des antigènes partagés |
JP7469807B2 (ja) | 2018-04-19 | 2024-04-17 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | Mage-b2特異性を有するt細胞受容体およびその使用 |
EP3796927A4 (fr) | 2018-05-23 | 2022-04-20 | Gritstone bio, Inc. | Antigènes partagés |
US20200291116A1 (en) | 2020-05-18 | 2020-09-17 | Abexxa Biologics, Inc. | Antibodies and methods of use thereof |
US20200291128A1 (en) | 2020-05-18 | 2020-09-17 | Abexxa Biologics, Inc. | Antibodies and methods of use thereof |
US20200291127A1 (en) | 2020-05-18 | 2020-09-17 | Abexxa Biologics, Inc. | Antibodies and methods of use thereof |
-
2015
- 2015-01-21 GB GBGB1501017.6A patent/GB201501017D0/en not_active Ceased
- 2015-12-16 EP EP19199098.5A patent/EP3616706B1/fr active Active
- 2015-12-16 PE PE2017000542A patent/PE20170940A1/es unknown
- 2015-12-16 CN CN202011429041.4A patent/CN112538109A/zh active Pending
- 2015-12-16 EA EA202190587A patent/EA202190587A3/ru unknown
- 2015-12-16 KR KR1020177017192A patent/KR102284493B1/ko active IP Right Grant
- 2015-12-16 MX MX2017008329A patent/MX2017008329A/es active IP Right Grant
- 2015-12-16 EP EP19199106.6A patent/EP3626730A1/fr not_active Withdrawn
- 2015-12-16 CN CN202011429073.4A patent/CN112646025A/zh active Pending
- 2015-12-16 MA MA40136A patent/MA40136A1/fr unknown
- 2015-12-16 CR CR20170282A patent/CR20170282A/es unknown
- 2015-12-16 DK DK19199125.6T patent/DK3626731T3/da active
- 2015-12-16 EP EP19199101.7A patent/EP3626729B1/fr active Active
- 2015-12-16 DK DK19170191.1T patent/DK3545965T3/da active
- 2015-12-16 SI SI201531682T patent/SI3545965T1/sl unknown
- 2015-12-16 BR BR112017008972-6A patent/BR112017008972A2/pt active Search and Examination
- 2015-12-16 WO PCT/EP2015/080018 patent/WO2016102272A1/fr active Application Filing
- 2015-12-16 SG SG11201703322UA patent/SG11201703322UA/en unknown
- 2015-12-16 MA MA49158A patent/MA49158B1/fr unknown
- 2015-12-16 EP EP15813809.9A patent/EP3236985B2/fr active Active
- 2015-12-16 RS RS20211276A patent/RS62448B1/sr unknown
- 2015-12-16 EP EP19199114.0A patent/EP3620168A1/fr not_active Withdrawn
- 2015-12-16 EA EA201791150A patent/EA201791150A1/ru unknown
- 2015-12-16 RS RS20211341A patent/RS62508B1/sr unknown
- 2015-12-16 EP EP19170191.1A patent/EP3545965B1/fr active Active
- 2015-12-16 MA MA41237A patent/MA41237B1/fr unknown
- 2015-12-16 CN CN202011432405.4A patent/CN112646021A/zh active Pending
- 2015-12-16 AU AU2015371490A patent/AU2015371490B2/en active Active
- 2015-12-16 CA CA2972126A patent/CA2972126A1/fr active Pending
- 2015-12-16 SI SI201531025T patent/SI3236985T2/sl unknown
- 2015-12-16 DK DK19199098.5T patent/DK3616706T3/da active
- 2015-12-16 EP EP20172206.3A patent/EP3715357A1/fr active Pending
- 2015-12-16 RS RS20211033A patent/RS62237B1/sr unknown
- 2015-12-16 RS RS20191606A patent/RS59836B2/sr unknown
- 2015-12-16 DK DK19199101.7T patent/DK3626729T3/da active
- 2015-12-16 EP EP19199125.6A patent/EP3626731B1/fr active Active
- 2015-12-16 CN CN201580055141.6A patent/CN107001414A/zh active Pending
- 2015-12-16 SI SI201531721T patent/SI3626729T1/sl unknown
- 2015-12-16 PL PL15813809.9T patent/PL3236985T5/pl unknown
- 2015-12-16 JP JP2017518096A patent/JP6906156B2/ja active Active
- 2015-12-21 US US14/975,952 patent/US10064926B2/en active Active
- 2015-12-21 TW TW104142988A patent/TWI687436B/zh active
- 2015-12-21 AR ARP150104228A patent/AR103220A1/es unknown
-
2016
- 2016-11-21 US US15/357,757 patent/US20170080070A1/en not_active Abandoned
-
2017
- 2017-03-07 IL IL250989A patent/IL250989B/en active IP Right Grant
- 2017-03-14 PH PH12017500484A patent/PH12017500484A1/en unknown
- 2017-05-31 CL CL2017001391A patent/CL2017001391A1/es unknown
-
2018
- 2018-03-09 US US15/917,098 patent/US20180207252A1/en not_active Abandoned
- 2018-03-12 US US15/918,788 patent/US11406693B2/en active Active
- 2018-09-18 US US16/134,422 patent/US20190000947A1/en not_active Abandoned
-
2020
- 2020-06-29 US US16/915,308 patent/US20200376103A1/en not_active Abandoned
- 2020-08-04 AU AU2020213294A patent/AU2020213294B2/en active Active
- 2020-08-04 AU AU2020213295A patent/AU2020213295B2/en active Active
- 2020-09-11 US US17/018,915 patent/US20200405831A1/en not_active Abandoned
-
2021
- 2021-03-26 JP JP2021052978A patent/JP2021104033A/ja active Pending
- 2021-04-30 US US17/245,918 patent/US11786583B2/en active Active
- 2021-07-14 AR ARP210101973A patent/AR122964A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA41237B1 (fr) | Nouveaux peptides et combinaisons de peptides pour une utilisation en immunothérapie contre le carcinome hépatocellulaire (chc) et autres cancers | |
MA46648A1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du pancréas et d'autres cancers | |
MA43490A1 (fr) | Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre divers cancers | |
MA44551A1 (fr) | Nouveaux peptides et nouvelle combinaison de peptides à utiliser en immunothérapie, et procédés pour générer des échafaudages à utiliser contre le cancer du pancréas et d'autres cancers | |
MA46508A1 (fr) | Nouveaux épitopes de cellules et nouvelle combinaison d'épitopes de cellules destinés à être utilisés dans l'immunothérapie du myélome et d'autres cancers | |
MA44101A (fr) | Peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer du sein et d'autres cancers | |
MA43459A1 (fr) | Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers | |
MA41393A1 (fr) | Nouveaux peptides et combinaisons de peptides et échafaudages formés de ceux-ci destinés à être utilisés en immunothérapie contre le carcinome colorectal (crc) et d'autres cancers | |
MA41520B2 (fr) | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers | |
MA43435B1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre diverses tumeurs (seq id 25 - mrax5-003) | |
MA46022B1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de la prostate et d'autres cancers | |
MA43330B1 (fr) | Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers | |
MA42381B1 (fr) | Nouveaux peptides et nouvelle combinaison de peptides à utiliser dans l'immunothérapie du cancer de l' oesophage et d'autres cancers | |
MA42294B1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers | |
MA43719B1 (fr) | Peptide à utiliser en immunothérapie contre le cancer du poumon non à petites cellules et le cancer du poumon à petites cellules | |
MA43328A1 (fr) | Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers | |
MA43090A1 (fr) | Peptides, combinaisons de peptides et médicaments basés sur les cellules pour l'immunothérapie contre le cancer de la vessie urinaire et d'autres cancers | |
MA47367B1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers | |
MA46913B1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers | |
MA41664A1 (fr) | Nouveaux peptides et nouvelle combinaison de peptides à utiliser en immunothérapie, et procédés pour générer des échafaudages à utiliser contre le cancer du pancréas et d'autres cancers | |
MA46503A1 (fr) | Nouveaux épitopes de cellules et nouvelle combinaison d'épitopes de cellules destinés à être utilisés dans l'immunothérapie du myélome et d'autres cancers |